治疗药物监测
钙调神经磷酸酶
他克莫司
医学
药理学
免疫抑制剂
治疗指标
细胞内
药品
移植
重症监护医学
内科学
生物
细胞生物学
作者
F. Lemaı̂tre,Nils Tore Vethe,Antonio D’Avolio,Camille Tron,Ida Robertsen,Brenda C. M. de Winter,Amedeo De Nicolò,Birgit C. P. Koch,Raman Venkataramanan,Teun van Gelder,Mercè Brunet,Stein Bergan,Dennis A. Hesselink,Pierre Wallemacq
标识
DOI:10.1097/ftd.0000000000000780
摘要
BACKGROUND: Therapeutic drug monitoring (TDM) of the 2 calcineurin inhibitors (CNIs), tacrolimus (TAC) and cyclosporin A, has resulted in improvements in the management of patients who have undergone solid organ transplantation. As a result of TDM, acute rejection (AR) rates and treatment-related toxicities have been reduced. Irrespective, AR and toxicity still occur in patients who have undergone transplantation, showing blood CNI concentrations within the therapeutic range. Moreover, the AR rate is no longer decreasing. Hence, smarter TDM approaches are necessary. Because CNIs exert their action inside T lymphocytes, intracellular CNIs may be a promising candidate for improving therapeutic outcomes. The intracellular CNI concentration may be more directly related to the drug effect and has been favorably compared with the standard, whole-blood TDM for TAC in liver transplant recipients. However, measuring intracellular CNIs concentrations is not without pitfalls at both the preanalytical and analytical stages, and standardization seems essential in this area. To date, there are no guidelines for the TDM of intracellular CNI concentrations. METHODS: Under the auspices of the International Association of TDM and Clinical Toxicology and its Immunosuppressive Drug committees, a group of leading investigators in this field have shared experiences and have presented preanalytical and analytical recommendations for measuring intracellular CNI concentrations.
科研通智能强力驱动
Strongly Powered by AbleSci AI